What is the Purpose of this Study?
The purpose of this study is to determine whether the addition of an investigational drug called LY3537982 to the current standard-of-care treatment (immunotherapy +/- chemotherapy) helps control cancer for a longer period of time and works better compared to receiving the standard-of-care treatment alone. Researchers aim to evaluate the safety and effectiveness of LY3537982 in people with KRAS G12C-mutant, locally advanced or metastatic non-small cell lung cancer (type of lung cancer caused by a gene alteration known as KRAS G12C). LY3537982 is small molecule that directly targets and blocks the KRAS G12C receptor, which has shown results in reducing the growth of tumors either on its own or in combination with other anticancer agents.
Eligibility
- * Histologically or cytologically confirmed NSCLC with Stage IIIB-IIIC or Stage IV disease, not suitable for curative intent radical surgery or radiation therapy.
- * Part B and Safety Lead-In Part B: the histology of the tumor must be predominantly non-squamous (in line with pemetrexed label).
- * Must have disease with evidence of KRAS G12C mutation.
- * Must have known programmed death-ligand 1 (PD-L1) expression
Where can I participate?
- CS Cancer at Beverly Hills : Garrett Crook
- CS Cancer at Cedars-Sinai Medical Center : Garrett Crook
- Hunt Cancer Institute, an Affiliate of Cedars-Sinai Cancer
More about this Clinical Trial
What is the full name of this clinical trial?
J3M-MC-JZQB: SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >=50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression